<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32305046
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1098-8785
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          18
         </day>
        </pubdate>
       </journalissue>
       <title>
        American journal of perinatology
       </title>
       <isoabbreviation>
        Am J Perinatol
       </isoabbreviation>
      </journal>
      <articletitle>
       Severe COVID-19 during Pregnancy and Possible Vertical Transmission.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1055/s-0040-1710050
      </elocationid>
      <abstract>
       <abstracttext>
        There are few cases of pregnant women with novel corona virus 2019 (COVID-19) in the literature, most of them with a mild illness course. There is limited evidence about in utero infection and early positive neonatal testing. A 41-year-old G3P2 with a history of previous cesarean deliveries and diabetes mellitus presented with a 4-day history of malaise, low-grade fever, and progressive shortness of breath. A nasopharyngeal swab was positive for COVID-19, COVID-19 serology was negative. The patient developed respiratory failure requiring mechanical ventilation on day 5 of disease onset. The patient underwent a cesarean delivery, and neonatal isolation was implemented immediately after birth, without delayed cord clamping or skin-to-skin contact. The neonatal nasopharyngeal swab, 16 hours after delivery, was positive for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) real-time polymerase chain reaction (RT-PCR), and immunoglobulin (Ig)-M and IgG for SARS-CoV-2 were negative. Maternal IgM and IgG were positive on postpartum day 4 (day 9 after symptom onset). We report a severe presentation of COVID-19 during pregnancy. To our knowledge, this is the earliest reported positive PCR in the neonate, raising the concern for vertical transmission. We suggest pregnant women should be considered as a high-risk group and minimize exposures for these reasons. KEY POINTS: · We report a severe presentation of COVID-19 in pregnancy requiring invasive ventilatory support.. · This is a case of positive RT-PCR in first day of life, suggesting possible vertical transmission.. · There were no detectable maternal antibodies for COVID-19 until after delivery..
       </abstracttext>
       <copyrightinformation>
        Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author equalcontrib="N" validyn="Y">
        <lastname>
         Alzamora
        </lastname>
        <forename>
         Maria Claudia
        </forename>
        <initials>
         MC
        </initials>
        <identifier source="ORCID">
         0000-0002-0905-713X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Division of Maternal Fetal Medicine, British American Hospital, Lima, Peru.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="N" validyn="Y">
        <lastname>
         Paredes
        </lastname>
        <forename>
         Tania
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Neonatology, British American Hospital, Lima, Peru.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="N" validyn="Y">
        <lastname>
         Caceres
        </lastname>
        <forename>
         David
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Pulmonary Medicine, British American Hospital, Lima, Peru.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="N" validyn="Y">
        <lastname>
         Webb
        </lastname>
        <forename>
         Camille M
        </forename>
        <initials>
         CM
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Disease, University of Texas Medical Branch, Texas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Tropical Medicine Institute "Alexander von Humbolt," Universidad Peruana Cayetano Heredia, Lima, Peru.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="N" validyn="Y">
        <lastname>
         Valdez
        </lastname>
        <forename>
         Luis M
        </forename>
        <initials>
         LM
        </initials>
        <affiliationinfo>
         <affiliation>
          Tropical Medicine Institute "Alexander von Humbolt," Universidad Peruana Cayetano Heredia, Lima, Peru.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Disease, British American Hospital, Lima, Peru.
         </affiliation>
        </affiliationinfo>
       </author>
       <author equalcontrib="N" validyn="Y">
        <lastname>
         La Rosa
        </lastname>
        <forename>
         Mauricio
        </forename>
        <initials>
         M
        </initials>
        <identifier source="ORCID">
         0000-0003-0183-1706
        </identifier>
        <affiliationinfo>
         <affiliation>
          Division of Maternal Fetal Medicine, British American Hospital, Lima, Peru.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Maternal Fetal Medicine, University of Texas Medical Branch, Texas.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        18
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Perinatol
      </medlineta>
      <nlmuniqueid>
       8405212
      </nlmuniqueid>
      <issnlinking>
       0735-1631
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <coistatement>
      None declared.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32305046
      </articleid>
      <articleid idtype="doi">
       10.1055/s-0040-1710050
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32305024
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1878-0334
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         14
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Diabetes &amp; metabolic syndrome
       </title>
       <isoabbreviation>
        Diabetes Metab Syndr
       </isoabbreviation>
      </journal>
      <articletitle>
       Artificial Intelligence (AI) applications for COVID-19 pandemic.
      </articletitle>
      <pagination>
       <medlinepgn>
        337-339
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1871-4021(20)30077-1
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.dsx.2020.04.012
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND AND AIMS" nlmcategory="OBJECTIVE">
        Healthcare delivery requires the support of new technologies like Artificial Intelligence (AI), Internet of Things (IoT), Big Data and Machine Learning to fight and look ahead against the new diseases. We aim to review the role of AI as a decisive technology to analyze, prepare us for prevention and fight with COVID-19 (Coronavirus) and other pandemics.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        The rapid review of the literature is done on the database of Pubmed, Scopus and Google Scholar using the keyword of COVID-19 or Coronavirus and Artificial Intelligence or AI. Collected the latest information regarding AI for COVID-19, then analyzed the same to identify its possible application for this disease.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        We have identified seven significant applications of AI for COVID-19 pandemic. This technology plays an important role to detect the cluster of cases and to predict where this virus will affect in future by collecting and analyzing all previous data.
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        Healthcare organizations are in an urgent need for decision-making technologies to handle this virus and help them in getting proper suggestions in real-time to avoid its spread. AI works in a proficient way to mimic like human intelligence. It may also play a vital role in understanding and suggesting the development of a vaccine for COVID-19. This result-driven technology is used for proper screening, analyzing, prediction and tracking of current patients and likely future patients. The significant applications are applied to tracks data of confirmed, recovered and death cases.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Vaishya
        </lastname>
        <forename>
         Raju
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Orthopaedics, Indraprastha Apollo Hospital, SaritaVihar, Mathura Road, 110076, New Delhi, India. Electronic address: raju.vaishya@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Javaid
        </lastname>
        <forename>
         Mohd
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Mechanical Engineering, Jamia Millia Islamia, New Delhi, India. Electronic address: mjavaid@jmi.ac.in.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Khan
        </lastname>
        <forename>
         Ibrahim Haleem
        </forename>
        <initials>
         IH
        </initials>
        <affiliationinfo>
         <affiliation>
          Jamia Hamdard, New Delhi, India. Electronic address: ibrahimhaleemkhan.ihk@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Haleem
        </lastname>
        <forename>
         Abid
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Mechanical Engineering, Jamia Millia Islamia, New Delhi, India. Electronic address: haleem.abid@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Diabetes Metab Syndr
      </medlineta>
      <nlmuniqueid>
       101462250
      </nlmuniqueid>
      <issnlinking>
       1871-4021
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       AI Applications
      </keyword>
      <keyword majortopicyn="N">
       Artificial Intelligence (AI)
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest None.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32305024
      </articleid>
      <articleid idtype="pii">
       S1871-4021(20)30077-1
      </articleid>
      <articleid idtype="doi">
       10.1016/j.dsx.2020.04.012
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32304747
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-1186
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Pharmacological research
       </title>
       <isoabbreviation>
        Pharmacol. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Angiotensin Receptor Blockers and 2019-nCoV.
      </articletitle>
      <pagination>
       <medlinepgn>
        104832
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1043-6618(20)31140-3
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.phrs.2020.104832
      </elocationid>
      <abstract>
       <abstracttext>
        Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current 2019-nCoV pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for 2019-nCoV patients.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Saavedra
        </lastname>
        <forename>
         Juan M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington D.C. 20057, USA. Electronic address: juan.saavedra@georgetown.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Pharmacol Res
      </medlineta>
      <nlmuniqueid>
       8907422
      </nlmuniqueid>
      <issnlinking>
       1043-6618
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       Angiotensin Receptor Blockers
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of Competing Interest The author has no conflict of interest to declare with respect to this manuscript.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32304747
      </articleid>
      <articleid idtype="pii">
       S1043-6618(20)31140-3
      </articleid>
      <articleid idtype="doi">
       10.1016/j.phrs.2020.104832
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32300267
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        0941-8849
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         27
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2018
         </year>
        </pubdate>
       </journalissue>
       <title>
        Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung
       </title>
       <isoabbreviation>
        Allergo J
       </isoabbreviation>
      </journal>
      <articletitle>
       Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?
      </articletitle>
      <pagination>
       <medlinepgn>
        28-45
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s15007-018-1580-4
      </elocationid>
      <abstract>
       <abstracttext label="Purpose" nlmcategory="UNASSIGNED">
        To provide current knowledge on respiratory virus-induced heterologous immunity (HI) with a focus on humoral and cellular cross-reactivity. Adaptive heterologous immune responses have broad implications on infection, autoimmunity, allergy and transplant immunology. A better understanding of the mechanisms involved might ultimately open up possibilities for disease prevention, for example by vaccination.
       </abstracttext>
       <abstracttext label="Methods" nlmcategory="UNASSIGNED">
        A structured literature search was performed using Medline and PubMed to provide an overview of the current knowledge on respiratory-virus induced adaptive HI.
       </abstracttext>
       <abstracttext label="Results" nlmcategory="UNASSIGNED">
        In HI the immune response towards one antigen results in an alteration of the immune response towards a second antigen. We provide an overview of respiratory virus-induced HI, including viruses such as respiratory syncytial virus (RSV), rhinovirus (RV), coronavirus (CoV) and influenza virus (IV). We discuss T cell receptor (TCR) and humoral cross-reactivity as mechanisms of HI involving those respiratory viruses. Topics covered include HI between respiratory viruses as well as between respiratory viruses and other pathogens. Newly developed vaccines, which have the potential to provide protection against multiple virus strains are also discussed. Furthermore, respiratory viruses have been implicated in the development of autoimmune diseases, such as narcolepsy, Guillain-Barré syndrome, type 1 diabetes or myocarditis. Finally, we discuss the role of respiratory viruses in asthma and the hygiene hypothesis, and review our recent findings on HI between IV and allergens, which leads to protection from experimental asthma.
       </abstracttext>
       <abstracttext label="Conclusion" nlmcategory="UNASSIGNED">
        Respiratory-virus induced HI may have protective but also detrimental effects on the host. Respiratory viral infections contribute to asthma or autoimmune disease development, but on the other hand, a lack of microbial encounter is associated with an increasing number of allergic as well as autoimmune diseases. Future research might help identify the elements which determine a protective or detrimental outcome in HI-based mechanisms.
       </abstracttext>
       <copyrightinformation>
        © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Pusch
        </lastname>
        <forename>
         Emanuel
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Laboratory Medicine, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.
         </affiliation>
         <identifier source="GRID">
          grid.10253.35
         </identifier>
         <identifier source="ISNI">
          0000 0004 1936 9756
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Renz
        </lastname>
        <forename>
         Harald
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Laboratory Medicine, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.
         </affiliation>
         <identifier source="GRID">
          grid.10253.35
         </identifier>
         <identifier source="ISNI">
          0000 0004 1936 9756
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Skevaki
        </lastname>
        <forename>
         Chrysanthi
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Laboratory Medicine, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.
         </affiliation>
         <identifier source="GRID">
          grid.10253.35
         </identifier>
         <identifier source="ISNI">
          0000 0004 1936 9756
         </identifier>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2018
       </year>
       <month>
        04
       </month>
       <day>
        26
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Allergo J
      </medlineta>
      <nlmuniqueid>
       9435413
      </nlmuniqueid>
      <issnlinking>
       0941-8849
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       adaptive immunity
      </keyword>
      <keyword majortopicyn="N">
       asthma
      </keyword>
      <keyword majortopicyn="N">
       autoimmunity
      </keyword>
      <keyword majortopicyn="N">
       cross-reactivity
      </keyword>
      <keyword majortopicyn="N">
       respiratory virus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2017
       </year>
       <month>
        12
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2018
       </year>
       <month>
        02
       </month>
       <day>
        15
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2018
       </year>
       <month>
        1
       </month>
       <day>
        1
       </day>
       <hour>
        0
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2018
       </year>
       <month>
        1
       </month>
       <day>
        1
       </day>
       <hour>
        0
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32300267
      </articleid>
      <articleid idtype="doi">
       10.1007/s15007-018-1580-4
      </articleid>
      <articleid idtype="pii">
       1580
      </articleid>
      <articleid idtype="pmc">
       PMC7149200
      </articleid>
     </articleidlist>
     <?pmcsd ?>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302812
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1879-1026
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         726
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          11
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Science of the total environment
       </title>
       <isoabbreviation>
        Sci. Total Environ.
       </isoabbreviation>
      </journal>
      <articletitle>
       Assessing nitrogen dioxide (NO
       <sub>
        2
       </sub>
       ) levels as a contributing factor to coronavirus (COVID-19) fatality.
      </articletitle>
      <pagination>
       <medlinepgn>
        138605
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0048-9697(20)32121-5
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.scitotenv.2020.138605
      </elocationid>
      <abstract>
       <abstracttext>
        Nitrogen dioxide (NO
        <sub>
         2
        </sub>
        ) is an ambient trace-gas result of both natural and anthropogenic processes. Long-term exposure to NO
        <sub>
         2
        </sub>
        may cause a wide spectrum of severe health problems such as hypertension, diabetes, heart and cardiovascular diseases and even death. The objective of this study is to examine the relationship between long-term exposure to NO
        <sub>
         2
        </sub>
        and coronavirus fatality. The Sentinel-5P is used for mapping the tropospheric NO
        <sub>
         2
        </sub>
        distribution and the NCEP/NCAR reanalysis for evaluating the atmospheric capability to disperse the pollution. The spatial analysis has been conducted on a regional scale and combined with the number of death cases taken from 66 administrative regions in Italy, Spain, France and Germany. Results show that out of the 4443 fatality cases, 3487 (78%) were in five regions located in north Italy and central Spain. Additionally, the same five regions show the highest NO
        <sub>
         2
        </sub>
        concentrations combined with downwards airflow which prevent an efficient dispersion of air pollution. These results indicate that the long-term exposure to this pollutant may be one of the most important contributors to fatality caused by the COVID-19 virus in these regions and maybe across the whole world.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier B.V. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ogen
        </lastname>
        <forename>
         Yaron
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          The Department of Remote Sensing and Cartography, Institute of Geosciences and Geography, Von-Seckendorff-Platz 4, Room: H4 2.23, Martin-Luther University Halle-Wittenberg, Halle (Saale) 06120, Germany. Electronic address: yaron.ogen@geo.uni-halle.de.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        11
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Sci Total Environ
      </medlineta>
      <nlmuniqueid>
       0330500
      </nlmuniqueid>
      <issnlinking>
       0048-9697
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Nitrogen dioxide (NO(2))
      </keyword>
      <keyword majortopicyn="N">
       Sentinel-5P
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302812
      </articleid>
      <articleid idtype="pii">
       S0048-9697(20)32121-5
      </articleid>
      <articleid idtype="doi">
       10.1016/j.scitotenv.2020.138605
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32301198
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1399-3062
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Transplant infectious disease : an official journal of the Transplantation Society
       </title>
       <isoabbreviation>
        Transpl Infect Dis
       </isoabbreviation>
      </journal>
      <articletitle>
       Case Report: A Kidney Transplant Patient with Mild COVID-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        e13296
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/tid.13296
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus Disease 2019 (COVID-19) is currently a pandemic with a mortality rate of 1-6% in the general population. However, the mortality rate seems to be significantly higher in elderly patients, especially those hospitalized with comorbidities, such as hypertension, diabetes, or coronary artery diseases. Because viral diseases may have atypical presentations in immunosuppressed patients, the course of the disease in the transplant patient population is unknown. Hence, the management of these patients with COVID-19 is an area of interest, and a unique approach is warranted. Here, we report the clinical features and our treatment approach for a kidney transplant patient with a diagnosis of COVID-19. We believe that screening protocols for SARS-Cov-2 should be re-evaluated in patients with solid-organ transplants.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Arpali
        </lastname>
        <forename>
         Emre
        </forename>
        <initials>
         E
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-6172-2398
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Akyollu
        </lastname>
        <forename>
         Basak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yelken
        </lastname>
        <forename>
         Berna
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tekin
        </lastname>
        <forename>
         Suda
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Disease, Koc University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Turkmen
        </lastname>
        <forename>
         Aydin
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kocak
        </lastname>
        <forename>
         Burak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Organ Transplantation, Koç University Hospital, İstanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D002363">
        Case Reports
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Denmark
      </country>
      <medlineta>
       Transpl Infect Dis
      </medlineta>
      <nlmuniqueid>
       100883688
      </nlmuniqueid>
      <issnlinking>
       1398-2273
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32301198
      </articleid>
      <articleid idtype="doi">
       10.1111/tid.13296
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32298984
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1878-0334
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         14
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Diabetes &amp; metabolic syndrome
       </title>
       <isoabbreviation>
        Diabetes Metab Syndr
       </isoabbreviation>
      </journal>
      <articletitle>
       Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis.
      </articletitle>
      <pagination>
       <medlinepgn>
        319-323
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1871-4021(20)30054-0
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.dsx.2020.03.014
      </elocationid>
      <abstract>
       <abstracttext label="INTRODUCTION" nlmcategory="BACKGROUND">
        and aims: To prevent the spread of coronavirus disease (COVID19) total lockdown is in place in India from March 24, 2020 for 21 days. In this study, we aim to assess the impact of the duration of the lockdown on glycaemic control and diabetes-related complications.
       </abstracttext>
       <abstracttext label="MATERIALS AND METHODS" nlmcategory="METHODS">
        A systematic search was conducted using Cochrane library. A simulation model was created using glycemic data from previous disasters (taken as similar in impact to current lockdown) taking baseline HBA1c and diabetes-related complications data from India-specific database. A multivariate regression analysis was conducted to analyse the relationship between the duration of lockdown and glycaemic targets &amp; diabetes-related complications.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        The predictive model was extremely robust (R2 = 0.99) and predicted outcomes for period of lockdown up to 90 days. The predicted increment in HBA1c from baseline at the end of 30 days and 45 days lockdown was projected as 2.26% &amp; 3.68% respectively. Similarly, the annual predicted percentage increase in complication rates at the end of 30-day lockdown was 2.8% for non-proliferative diabetic retinopathy, 2.9% for proliferative diabetic retinopathy, 1.5% for retinal photocoagulation, 9.3% for microalbuminuria, 14.2% for proteinuria, 2.9% for peripheral neuropathy, 10.5% for lower extremity amputation, 0.9% for myocardial infarction, 0.5% for stroke and 0.5% for infections.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        The duration of lockdown is directly proportional to the worsening of glycaemic control and diabetes-related complications. Such increase in diabetes-related complications will put additional load on overburdened healthcare system, and also increase COVID19 infections in patients with such uncontrolled glycemia.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020. Published by Elsevier Ltd.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ghosal
        </lastname>
        <forename>
         Samit
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Nightingale Hospital, Kolkata, India. Electronic address: ramdasghosal@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sinha
        </lastname>
        <forename>
         Binayak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          AMRI Hospitals, Kolkata, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Majumder
        </lastname>
        <forename>
         Milan
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Milan Majumder, Biostatistician, Pune, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Anoop
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Fortis CDOC Hospital for Diabetes and Allied Sciences, New Delhi, India; Diabetes Foundation (India), National Diabetes Obesity and Cholesterol Foundation (NDOC), New Delhi, India.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Diabetes Metab Syndr
      </medlineta>
      <nlmuniqueid>
       101462250
      </nlmuniqueid>
      <issnlinking>
       1871-4021
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Complications
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Disaster
      </keyword>
      <keyword majortopicyn="N">
       Lockdown
      </keyword>
      <keyword majortopicyn="N">
       Multivariate regression analysis
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest None to declare.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298984
      </articleid>
      <articleid idtype="pii">
       S1871-4021(20)30054-0
      </articleid>
      <articleid idtype="doi">
       10.1016/j.dsx.2020.03.014
      </articleid>
      <articleid idtype="pmc">
       PMC7146694
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Indian J Endocrinol Metab. 2014 May;18(3):370-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24944934
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arch Intern Med. 1998 Feb 9;158(3):274-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9472208
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):560-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22851189
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Diabet Med. 1993 Oct;10(8):774-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8261762
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2020 Mar 26;368:m1198
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32217618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Diabetes Care. 2009 Sep;32(9):1632-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19542210
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Endocr J. 2004 Aug;51(4):407-14
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15351797
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Diabetes Res Clin Pract. 1997 Jun;36(3):193-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9237786
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Med J Aust. 2003 Nov 3;179(9):498-503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14583083
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32298982
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1878-0334
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         14
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        Diabetes &amp; metabolic syndrome
       </title>
       <isoabbreviation>
        Diabetes Metab Syndr
       </isoabbreviation>
      </journal>
      <articletitle>
       Prediction of the number of deaths in India due to SARS-CoV-2 at 5-6 weeks.
      </articletitle>
      <pagination>
       <medlinepgn>
        311-315
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1871-4021(20)30057-6
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.dsx.2020.03.017
      </elocationid>
      <abstract>
       <abstracttext label="INTRODUCTION" nlmcategory="BACKGROUND">
        and Aims: No valid treatment or preventative strategy has evolved till date to counter the SARS CoV 2 (Novel Coronavirus) epidemic that originated in China in late 2019 and have since wrought havoc on millions across the world with illness, socioeconomic recession and death. This analysis was aimed at tracing a trend related to death counts expected at the 5th and 6th week of the COVID-19 in India.
       </abstracttext>
       <abstracttext label="MATERIAL AND METHODS" nlmcategory="METHODS">
        Validated database was used to procure global and Indian data related to coronavirus and related outcomes. Multiple regression and linear regression analyses were used interchangeably. Since the week 6 death count data was not correlated significantly with any of the chosen inputs, an auto-regression technique was employed to improve the predictive ability of the regression model.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        A linear regression analysis predicted average week 5 death count to be 211 with a 95% CI: 1.31-2.60). Similarly, week 6 death count, in spite of a strong correlation with input variables, did not pass the test of statistical significance. Using auto-regression technique and using week 5 death count as input the linear regression model predicted week 6 death count in India to be 467, while keeping at the back of our mind the risk of over-estimation by most of the risk-based models.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
        According to our analysis, if situation continue in present state; projected death rate (n) is 211 and467 at the end of the 5th and 6th week from now, respectively.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ghosal
        </lastname>
        <forename>
         Samit
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant Endocrinologist. Nightingale Hospital, Kolkata, India. Electronic address: ramdasghosal@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sengupta
        </lastname>
        <forename>
         Sumit
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant Pulmonologist. AMRI Hospitals, Kolkata, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Majumder
        </lastname>
        <forename>
         Milan
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Milan Majumder, Independent Statistician, Pune, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sinha
        </lastname>
        <forename>
         Binayak
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant Endocrinologist. AMRI Hospitals, Kolkata, India.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Diabetes Metab Syndr
      </medlineta>
      <nlmuniqueid>
       101462250
      </nlmuniqueid>
      <issnlinking>
       1871-4021
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Correlation
      </keyword>
      <keyword majortopicyn="N">
       Death rates
      </keyword>
      <keyword majortopicyn="N">
       India
      </keyword>
      <keyword majortopicyn="N">
       Regression
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest None to declare.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        26
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298982
      </articleid>
      <articleid idtype="pii">
       S1871-4021(20)30057-6
      </articleid>
      <articleid idtype="doi">
       10.1016/j.dsx.2020.03.017
      </articleid>
      <articleid idtype="pmc">
       PMC7128942
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Curr Top Microbiol Immunol. 2005;287:1-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15609507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32298251
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1545-861X
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         69
        </volume>
        <issue>
         15
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        MMWR. Morbidity and mortality weekly report
       </title>
       <isoabbreviation>
        MMWR Morb. Mortal. Wkly. Rep.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.
      </articletitle>
      <pagination>
       <medlinepgn>
        458-464
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.15585/mmwr.mm6915e3
      </elocationid>
      <abstract>
       <abstracttext>
        Since SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in December 2019 (1), approximately 1.3 million cases have been reported worldwide (2), including approximately 330,000 in the United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in the United States, the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) was created using the existing infrastructure of the Influenza Hospitalization Surveillance Network (FluSurv-NET) (4) and the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET). This report presents age-stratified COVID-19-associated hospitalization rates for patients admitted during March 1-28, 2020, and clinical data on patients admitted during March 1-30, 2020, the first month of U.S. surveillance. Among 1,482 patients hospitalized with COVID-19, 74.5% were aged ≥50 years, and 54.4% were male. The hospitalization rate among patients identified through COVID-NET during this 4-week period was 4.6 per 100,000 population. Rates were highest (13.8) among adults aged ≥65 years. Among 178 (12%) adult patients with data on underlying conditions as of March 30, 2020, 89.3% had one or more underlying conditions; the most common were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). These findings suggest that older adults have elevated rates of COVID-19-associated hospitalization and the majority of persons hospitalized with COVID-19 have underlying medical conditions. These findings underscore the importance of preventive measures (e.g., social distancing, respiratory hygiene, and wearing face coverings in public settings where social distancing measures are difficult to maintain)
        <sup>
         †
        </sup>
        to protect older adults and persons with underlying medical conditions, as well as the general public. In addition, older adults and persons with serious underlying medical conditions should avoid contact with persons who are ill and immediately contact their health care provider(s) if they have symptoms consistent with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html) (5). Ongoing monitoring of hospitalization rates, clinical characteristics, and outcomes of hospitalized patients will be important to better understand the evolving epidemiology of COVID-19 in the United States and the clinical spectrum of disease, and to help guide planning and prioritization of health care system resources.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Garg
        </lastname>
        <forename>
         Shikha
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Lindsay
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Whitaker
        </lastname>
        <forename>
         Michael
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         O'Halloran
        </lastname>
        <forename>
         Alissa
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Cummings
        </lastname>
        <forename>
         Charisse
        </forename>
        <initials>
         C
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Holstein
        </lastname>
        <forename>
         Rachel
        </forename>
        <initials>
         R
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Prill
        </lastname>
        <forename>
         Mila
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Chai
        </lastname>
        <forename>
         Shua J
        </forename>
        <initials>
         SJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kirley
        </lastname>
        <forename>
         Pam D
        </forename>
        <initials>
         PD
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Alden
        </lastname>
        <forename>
         Nisha B
        </forename>
        <initials>
         NB
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kawasaki
        </lastname>
        <forename>
         Breanna
        </forename>
        <initials>
         B
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Yousey-Hindes
        </lastname>
        <forename>
         Kimberly
        </forename>
        <initials>
         K
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Niccolai
        </lastname>
        <forename>
         Linda
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Anderson
        </lastname>
        <forename>
         Evan J
        </forename>
        <initials>
         EJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Openo
        </lastname>
        <forename>
         Kyle P
        </forename>
        <initials>
         KP
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Weigel
        </lastname>
        <forename>
         Andrew
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Monroe
        </lastname>
        <forename>
         Maya L
        </forename>
        <initials>
         ML
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Ryan
        </lastname>
        <forename>
         Patricia
        </forename>
        <initials>
         P
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Henderson
        </lastname>
        <forename>
         Justin
        </forename>
        <initials>
         J
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Sue
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Como-Sabetti
        </lastname>
        <forename>
         Kathy
        </forename>
        <initials>
         K
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Lynfield
        </lastname>
        <forename>
         Ruth
        </forename>
        <initials>
         R
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Sosin
        </lastname>
        <forename>
         Daniel
        </forename>
        <initials>
         D
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Torres
        </lastname>
        <forename>
         Salina
        </forename>
        <initials>
         S
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Muse
        </lastname>
        <forename>
         Alison
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Bennett
        </lastname>
        <forename>
         Nancy M
        </forename>
        <initials>
         NM
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Billing
        </lastname>
        <forename>
         Laurie
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Sutton
        </lastname>
        <forename>
         Melissa
        </forename>
        <initials>
         M
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         West
        </lastname>
        <forename>
         Nicole
        </forename>
        <initials>
         N
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Schaffner
        </lastname>
        <forename>
         William
        </forename>
        <initials>
         W
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Talbot
        </lastname>
        <forename>
         H Keipp
        </forename>
        <initials>
         HK
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Aquino
        </lastname>
        <forename>
         Clarissa
        </forename>
        <initials>
         C
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         George
        </lastname>
        <forename>
         Andrea
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Budd
        </lastname>
        <forename>
         Alicia
        </forename>
        <initials>
         A
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Brammer
        </lastname>
        <forename>
         Lynnette
        </forename>
        <initials>
         L
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Langley
        </lastname>
        <forename>
         Gayle
        </forename>
        <initials>
         G
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Hall
        </lastname>
        <forename>
         Aron J
        </forename>
        <initials>
         AJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Fry
        </lastname>
        <forename>
         Alicia
        </forename>
        <initials>
         A
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016425">
        Published Erratum
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       MMWR Morb Mortal Wkly Rep
      </medlineta>
      <nlmuniqueid>
       7802429
      </nlmuniqueid>
      <issnlinking>
       0149-2195
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <coistatement>
      All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Linda Niccolai reports personal fees from Merck outside the submitted work; Evan Anderson reports personal fees from AbbVie and Pfizer, and grants from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron, outside the submitted work; Andrew Weigel reports grants from the Council of State and Territorial Epidemiologists during the conduct of the study; Ruth Lynfield reports that she is the coeditor for a book on public health and an associate editor for American Academy of Pediatrics Report of the Committee of Infectious Diseases (Red Book); Laurie Billing reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; William Schaffner reports personal fees from Pfizer, Roche Diagnostics, and Pepsico outside the submitted work; H. Keipp Talbot reports compensation from Seqiris outside the submitted work; Andrea George reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; Sue Kim reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; Justin Henderson reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study; and Clarissa Aquino reports a grant from the Council of State and Territorial Epidemiologists during the conduct of the study. No other potential conflicts of interest were disclosed.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298251
      </articleid>
      <articleid idtype="doi">
       10.15585/mmwr.mm6915e3
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32298145
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1941-7705
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Circulation. Cardiovascular quality and outcomes
       </title>
       <isoabbreviation>
        Circ Cardiovasc Qual Outcomes
       </isoabbreviation>
      </journal>
      <articletitle>
       The Role of Data Registries in the Time of COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/CIRCOUTCOMES.120.006766
      </elocationid>
      <abstract>
       <abstracttext>
        On April 1, 2020, the confirmed global burden of COVID-19 was more than 900,000 with 46,413 deaths. Despite worldwide calls for social distancing and containment, the incidence of the disease continues to increase. COVID-19 is a respiratory tract infection caused by the novel coronavirus (SARS-CoV2). Preliminary analyses from the Chinese Center for Disease Control and Prevention indicated an overall case fatality rate (CFR) of 2.3%; however the CFR was higher in older adults (14.8% in those 80± years) and 49% of all critical cases. Those with preexisting conditions (cardiovascular disease (CVD), diabetes, chronic respiratory disease, hypertension, and cancer) also had higher CRFs. In the United States, 116 million adults have hypertension, 26 million US adults have diabetes mellitus, 9% have preexisting CVD and may therefore be at greater risk of complications or adverse health outcomes from COVID-19 infection.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alger
        </lastname>
        <forename>
         Heather M
        </forename>
        <initials>
         HM
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Williams Iv
        </lastname>
        <forename>
         Joseph H
        </forename>
        <initials>
         JH
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Walchok
        </lastname>
        <forename>
         Jason G
        </forename>
        <initials>
         JG
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bolles
        </lastname>
        <forename>
         Michele M
        </forename>
        <initials>
         MM
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fonarow
        </lastname>
        <forename>
         Gregg C
        </forename>
        <initials>
         GC
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, University of California Los Angeles, CA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rutan
        </lastname>
        <forename>
         Christine
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          American Heart Association, Dallas, TX.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Circ Cardiovasc Qual Outcomes
      </medlineta>
      <nlmuniqueid>
       101489148
      </nlmuniqueid>
      <issnlinking>
       1941-7713
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Get With The Guidelines
      </keyword>
      <keyword majortopicyn="N">
       atrial fibrillation
      </keyword>
      <keyword majortopicyn="N">
       coronary artery disease
      </keyword>
      <keyword majortopicyn="N">
       database
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298145
      </articleid>
      <articleid idtype="doi">
       10.1161/CIRCOUTCOMES.120.006766
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32295322
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        1001-0939
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
       </title>
       <isoabbreviation>
        Zhonghua Jie He He Hu Xi Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province].
      </articletitle>
      <pagination>
       <medlinepgn>
        E042
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.cn112147-20200224-00168
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Objective:
        </b>
        To analyze the epidemiological characteristics and clinical features of the patients with 2019-nCoV infection in Nanyang City, so as to provide evidence for clinical diagnosis and treatment.
        <b>
         Methods:
        </b>
        The epidemiology, clinical symptoms, atory and radiologic data of 150 patients with 2019-nCoV infection admitted to the designated hospitals in Nanyang City from January 24,2020 to February 16, 2020 were retrospectively analyzed.
        <b>
         Results:
        </b>
        The 150 patients with 2019 nCov infection consisted of 67 men and 83 women, and the median age was 45±16 years; 69 of them were the first generation case,60 of them were the second generation case, 6 of them were the third generation case,the median incubation period of the first generation case was 5.4±2.2 days, and the second generation case was 6.7±3.1 days, and the first-generation cases are the majority in severe patients (69%) . The most common basic disease was hypertension (13 cases, 9%), diabetes (9 cases, 6%), and the most common symptom is fever(142 cases, 95%, 63% showed moderate fever) , cough and sputum(108 cases,72%), fatigue(23 cases,15%), anorexia(20 cases, 13%), headache, diarrhea, muscle soreness, sore throat as the first symptoms. The average time from onset of symptoms to consultation was 4.2±2.2 days for all patients. The changes in peripheral blood cells were mainly lymphonpenia (83 cases, 55%) and eosinophilia (95 cases, 63%), The lymphocyte count of the severe and critically ill patients was more significantly reduced, and some patients had increased myocardial enzymes, mainly LDH (47 cases, 31%), and a few patients had liver function damage, mainly manifested in ALT and AST. High, very few patients have renal impairment. Among the inflammation-related indicators, the main manifestations are increased CRP (66 cases, 43%) and ESR (86 cases, 57%), elevated D-Dimer in 29% of patients. 144 cases have different degrees of infective lesions in chest CT examination, with 30 cases (21%) on one side and 144 cases (79%) on both sides. Morphologically, most of the lesions were patchy ground glass lesions, which could be accompanied by air bronchus signs and some consolidation and paving stone signs. Of the cases showing "white lung", 87% were sever ill or critically ill. After active treatment, 45% of patients were discharged according to discharge standards. 33% of sever and critically ill patients were discharged, 49% of them were degraded hospitalization.The average length of hospitalization was 12±4 days.
        <b>
         Conclusion:
        </b>
        A history of epidemiological exposure, fever, chest CT with signs of pneumonia, normal or decreased WBC, and lymphocytopenia, eosinophilia are the clinical basis for the diagnosis of this disease, and most of the sever patients were the first generation cases. The degree of lymphocytopenia is related to the severity of the disease.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         C
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         X B
        </forename>
        <initials>
         XB
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dai
        </lastname>
        <forename>
         Y
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         X Z
        </forename>
        <initials>
         XZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         J
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Disease and Intensive Care, Nanyang Central Hospital, Nanyang 473000, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <publicationtypelist>
       <publicationtype ui="D004740">
        English Abstract
       </publicationtype>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Jie He He Hu Xi Za Zhi
      </medlineta>
      <nlmuniqueid>
       8712226
      </nlmuniqueid>
      <issnlinking>
       1001-0939
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       <b>
        目的：
       </b>
       分析河南省南阳市2019新型冠状病毒（2019-nCoV）感染患者的流行病学和临床特点，为临床诊治提供依据。
       <b>
        方法：
       </b>
       对2020年1月24日至2020年2月16日在南阳市各定点医院收治的150例2019-nCoV感染患者的流行病学、临床症状、实验室和影像学资料进行回顾性分析，其中男67例，女83例，年龄3~98岁，平均（45±16）岁。
       <b>
        结果：
       </b>
       150例2019-nCoV感染患者中，一代病例69例（69/150，45%），二代病例60例（60/150，40%），三代病例6例（6/150，4%）；一代病例平均潜伏期为（5.4±2.2）d，二代病例平均潜伏期为（6.7±3.1）d，重症患者中一代病例占多数（69%）。患者最常见的基础疾病为高血压（13/150，8%），其次为糖尿病（9/150，6%）；最常见的症状为发热（142/150，95%），多表现为中等发热（38.1~39.0 ℃，90/150，63%），较常见的临床症状为咳嗽咳痰（108/150，72%）、乏力（23/150，15%）、纳差（20/150，13%），少数患者以头痛、腹泻、肌肉酸痛、咽痛为首发症状。所有患者从出现首发症状到就诊平均时间为（4.2±2.2）d。外周血细胞学改变主要为淋巴细胞（83/150，55%）及嗜酸粒细胞减低（95/150，63%），重症及危重症患者淋巴细胞计数降低更显著，部分患者出现心肌酶升高，主要为LDH升高（47/150，31%），少数患者出现肝功能损伤，主要表现为丙氨酸氨基转移酶、天冬氨酸基转移酶升高，极少数患者出现肾功能损伤。炎症相关指标中，主要表现为C反应蛋白（66/150，43%）及ESR（86/150，57%）升高，29%患者D-二聚体升高。所有患者均行胸部CT检查，其中144例存在不同程度的感染性改变，30例累及单肺，114例累及双肺，形态学以斑片状磨玻璃病灶居多，可伴空气支气管征及部分实变及铺路石征；7例影像学呈"白肺"表现，多为重症或危重症患者。经积极治疗，67例患者符合出院标准出院，39例危重症患者中13例出院，19例降级住院，出院患者平均住院时间为（12±4）d。
       <b>
        结论：
       </b>
       有流行病学接触史、发热、胸部CT有肺炎征象及白细胞正常或减少、淋巴细胞减少是诊断本病的临床依据，重症患者多为一代病例，淋巴细胞降低程度与疾病的严重程度呈相关性。.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019 Novel coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32295322
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.cn112147-20200224-00168
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32294858
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        0376-2491
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         100
        </volume>
        <issue>
         13
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua yi xue za zhi
       </title>
       <isoabbreviation>
        Zhonghua Yi Xue Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [CT imaging analysis of 33 cases with the 2019 novel coronavirus infection].
      </articletitle>
      <pagination>
       <medlinepgn>
        1007-1011
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.cn112137-20200203-00182
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Objective:
        </b>
        To explore the CT imaging features of the 2019 novel coronavirus (2019-nCoV) infection in order to summarize the imaging characteristics of the disease and improve the ability of imaging diagnosis and early diagnosis of the disease.
        <b>
         Methods:
        </b>
        From January 13, 2020 to January 31, 2020, a total of 33 patients with 2019-nCoV infection diagnosed and treated by Suzhou Fifth People's Hospital were analyzed retrospectively, including 20 males and 13 females, with an average age of (50±12) years, ranging from 20 to 70 years old. There were 3 cases of mild type, 27 cases of common type and 3 cases of severe type.There were 2 cases with hypertension, 1 case with postoperative lung,1 case with diabetes, 1 case with chronic bronchitis, and 1 case with bronchiectasis.SPSS25.0 Chi-square test was used to analyze the distribution of lesions in each lung lobe; SPSS25.0 Spearman correlation coefficient was used to analyze the image score and clinical classification.
        <b>
         Results:
        </b>
        There were 3 cases (9.1%) with normal lung and 30 cases (90.9%) with Novel Coronavirus Pneumonia(COVID-19) of the 2019-nCoV infected patients. In the distribution of COVID-19, 29 cases (87.9%) were involved in bilateral lung and 1 case (3.0%) in unilateral lung. There was no statistically significant difference in the distribution of lesions in each lobe. The correlation coefficient between the degree of lesion distribution and clinical classification was 0.819, and the two were highly correlated.There were 30 cases (90.9%) with subpleural lesions, 17 cases (51.5%) with central lesions. There were many kinds of lesions, 25 cases (75.8%) had ground glass density shadow, 16 cases (48.5%) had consolidation, 12 cases (36.4%) had interstitial change, and 18 cases (54.5%) had interlobular septal thickening. Among the 22 cases, 10 cases had more lesions, 6 cases had no changes and 6 cases had less lesions.
        <b>
         Conclusion:
        </b>
        Most of the patients with 2019-nCoV infection have pulmonary inflammation.CT manifestations include multiple parts, subpleural area or middle and lateral field of lung, ground glass shadow and consolidation, or coexistence. Some cases have pleural thickening or interlobular septal thickening. CT images can indicate the diagnosis of COVID-19 and provide important basis for early detection and disease monitoring.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         R R
        </forename>
        <initials>
         RR
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Y
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         M Y
        </forename>
        <initials>
         MY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         J
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ren
        </lastname>
        <forename>
         R
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cao
        </lastname>
        <forename>
         Q L
        </forename>
        <initials>
         QL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shen
        </lastname>
        <forename>
         X H
        </forename>
        <initials>
         XH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         G Q
        </forename>
        <initials>
         GQ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Second Affiliated Hospital, Soochow University, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         M
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, the Affiliated Infectious Diseases Hospital of Soochow University, the Fifth People's Hospital of Suzhou, Suzhou 215000, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         SYS2020022
        </grantid>
        <agency>
         Suzhou Scientific and Technological Project for Emergency Prevention and Treatment of Novel Coronavirus Infection
        </agency>
        <country>
        </country>
       </grant>
       <grant>
        <grantid>
         Szzx201508
        </grantid>
        <agency>
         Clinical Center for Infectious Diseases
        </agency>
        <country>
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Yi Xue Za Zhi
      </medlineta>
      <nlmuniqueid>
       7511141
      </nlmuniqueid>
      <issnlinking>
       0376-2491
      </issnlinking>
     </medlinejournalinfo>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000657964">
       COVID-19 diagnostic testing
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000328">
        Adult
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000368">
        Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019411">
        Clinical Laboratory Techniques
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015897">
        Comorbidity
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D042241">
        Early Diagnosis
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005260">
        Female
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007249">
        Inflammation
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D008168">
        Lung
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008875">
        Middle Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000000981">
        diagnostic imaging
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012189">
        Retrospective Studies
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012720">
        Severity of Illness Index
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014057">
        Tomography, X-Ray Computed
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D055815">
        Young Adult
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       <b>
        目的：
       </b>
       探讨新型冠状病毒（2019-nCoV）感染患者的肺部CT影像表现，总结其影像特征，提高对该病肺部影像诊断能力。
       <b>
        方法：
       </b>
       回顾性分析2020年1月13至31日苏州市第五人民医院诊治的33例2019-nCoV感染患者，男20例、女13例，年龄20~70（50±12）岁。轻型3例，普通型27例，重型3例。其中合并高血压2例，肺部术后、糖尿病、慢性支气管炎、支气管扩张各1例。运用SPSS 25.0软件对各肺叶分布及分布范围与临床相关性进行统计学分析。
       <b>
        结果：
       </b>
       2019-nCoV感染者肺部无异常3例（9.1%），新型冠状病毒肺炎（COVID-19）30例（90.9%）。COVID-19在分布上累及双肺29例（87.9%），累及单侧1例（3.0%）。病变在各肺叶分布的差异无统计学意义，病变分布范围与临床分型之间相关系数为0.819，两者具有高度相关。胸膜下区病变30例（90.9%），其中合并中央区同时存在17例（51.5%）。病变表现为多种病变及合并存在，磨玻璃密度影25例（75.8%），实变16例（48.5%），间质改变12例（36.4%），小叶间隔增厚18例（54.5%）。22例复查者，病变增多10例，病变无变化6例，病变减少6例。
       <b>
        结论：
       </b>
       2019-nCoV感染者多有肺部炎症，CT表现为多部位、胸膜下区或外中带多见、磨玻璃密度和实变多见或共存；部分合并胸膜增厚或小叶间隔增厚。CT影像能够提示COVID-19诊断，对早期发现和病情监测提供重要依据。.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       Lung
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
      <keyword majortopicyn="N">
       Tomography, X-ray computed
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294858
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.cn112137-20200203-00182
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32294179
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1945-7189
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Endocrine reviews
       </title>
       <isoabbreviation>
        Endocr. Rev.
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       bnaa011
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1210/endrev/bnaa011
      </elocationid>
      <abstract>
       <abstracttext>
        Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
       </abstracttext>
       <copyrightinformation>
        © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Drucker
        </lastname>
        <forename>
         Daniel J
        </forename>
        <initials>
         DJ
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Endocr Rev
      </medlineta>
      <nlmuniqueid>
       8006258
      </nlmuniqueid>
      <issnlinking>
       0163-769X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Angiotensin Converting Enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Dipeptidyl Peptidase-4
      </keyword>
      <keyword majortopicyn="N">
       Obesity
      </keyword>
      <keyword majortopicyn="N">
       Receptor
      </keyword>
      <keyword majortopicyn="N">
       Virus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294179
      </articleid>
      <articleid idtype="pii">
       5820492
      </articleid>
      <articleid idtype="doi">
       10.1210/endrev/bnaa011
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32293710
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-9071
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of medical virology
       </title>
       <isoabbreviation>
        J. Med. Virol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/jmv.25887
      </elocationid>
      <abstract>
       <abstracttext>
        COVID-19 infection and its severity can be explained by the concentration of glycosylated SARS- CoV-2 viral particles in the lung epithelium, the concentration of glycosylated angiotensin converting enzyme receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8-10 after symptom onset, which may be related to both. Binding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease. It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV- 2 spike protein form at day 7-10, results in acute respiratory distress syndrome (ARDS) in susceptible patients. It is also allows consideration of agents, such as hydroxychloroquine, which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate the M1 to M2 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS. This article is protected by copyright. All rights reserved.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Brufsky
        </lastname>
        <forename>
         Adam
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-8080-7960
        </identifier>
        <affiliationinfo>
         <affiliation>
          UPMC Hillman Cancer Center, Magee Women's Hospital, University of Pittsburgh School of Medicine, Suite 4628, 300 Halket Street, Pittsburgh, PA, 15213.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Med Virol
      </medlineta>
      <nlmuniqueid>
       7705876
      </nlmuniqueid>
      <issnlinking>
       0146-6615
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       SARS coronavirus
      </keyword>
      <keyword majortopicyn="N">
       antibody-mediated cell-mediated cytotoxicity
      </keyword>
      <keyword majortopicyn="N">
       antiviral agents
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293710
      </articleid>
      <articleid idtype="doi">
       10.1002/jmv.25887
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292261
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2213-686X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of King Saud University. Science
       </title>
       <isoabbreviation>
        J King Saud Univ Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       Biological and Epidemiological Trends in the Prevalence and Mortality due to Outbreaks of Novel Coronavirus COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.jksus.2020.04.004
      </elocationid>
      <abstract>
       <abstracttext>
        The novel coronavirus (Covid-19) infection outbreak has posed a major threat to international health system and economy. This study is aimed at investigating the biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus (COVID-19) infections. The data on the global outbreak of COVID-19, were obtained from World Health Organization (WHO), Worldometer, Centers for Disease Control and Prevention (CDC), and research institutes. The information was also recorded from research documents published in global scientific journals indexed in Pub Med and Institute of Scientific Information (ISI) Web of Science on the trends in the prevalence and mortality due to COVID-19 infection outbreaks. The results show rising trends in the transmission, prevalence and mortality rate due to coronavirus COVID-19. During the period of December 29, 2019 through March 31, 2020, it has infected 750890 people worldwide, resulting in 36405 deaths with a mortality rate of 4.84%. The infections were more frequent among male gender with above 60 years of age. The mean growth rate index for total number of cases from January 23 to March 31, 2020 was 1.20 and growth rate index for mortality rate was 1.12. There was a positive association between the prevalence and mortality rate (R
        <sup>
         2
        </sup>
        =0.996). The novel coronavirus COVID-19 is highly contagious and has affected a large number of people worldwide. It is still spreading with mutable prevalence and mortality outbreak trends. The global health officials have taken priority measures to prevent the further outbreaks of this emerging pathogen across the globe. However, the rising number of cases and mortality risk estimates are demonstrating that enhanced public health mediations, good hygienic conditions, social distancing and movement limitations may control the COVID-19 epidemics.
       </abstracttext>
       <copyrightinformation>
        © 2020 Published by Elsevier B.V. on behalf of King Saud University.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Meo
        </lastname>
        <forename>
         Sultan Ayoub
        </forename>
        <initials>
         SA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Al-Khlaiwi
        </lastname>
        <forename>
         Thamir
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Strategic Centre for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Usmani
        </lastname>
        <forename>
         Adnan Mahmood
        </forename>
        <initials>
         AM
        </initials>
        <affiliationinfo>
         <affiliation>
          Army Medical College, National University of Health Sciences, Rawalpindi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Meo
        </lastname>
        <forename>
         Anusha Sultan
        </forename>
        <initials>
         AS
        </initials>
        <affiliationinfo>
         <affiliation>
          Diabetes Research Institute, Mills-Peninsula Medical Center (Sutter Health), San Mateo, California, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Klonoff
        </lastname>
        <forename>
         David C
        </forename>
        <initials>
         DC
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Strategic Centre for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Army Medical College, National University of Health Sciences, Rawalpindi, Pakistan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Diabetes Research Institute, Mills-Peninsula Medical Center (Sutter Health), San Mateo, California, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Walter Reed National Medical Center, Bethesda, MD, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hoang
        </lastname>
        <forename>
         Thanh D
        </forename>
        <initials>
         TD
        </initials>
        <affiliationinfo>
         <affiliation>
          Walter Reed National Medical Center, Bethesda, MD, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Saudi Arabia
      </country>
      <medlineta>
       J King Saud Univ Sci
      </medlineta>
      <nlmuniqueid>
       9886378
      </nlmuniqueid>
      <issnlinking>
       1018-3647
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       Biological trends
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Covid-2019
      </keyword>
      <keyword majortopicyn="N">
       Outbreak
      </keyword>
      <keyword majortopicyn="N">
       Prevalence
      </keyword>
     </keywordlist>
     <coistatement>
      The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        02
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292261
      </articleid>
      <articleid idtype="doi">
       10.1016/j.jksus.2020.04.004
      </articleid>
      <articleid idtype="pii">
       S1018-3647(20)30151-8
      </articleid>
      <articleid idtype="pmc">
       PMC7144605
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3913-3918
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29949167
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32141570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30070331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2003 Oct 25;362(9393):1353-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585636
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Jan;577(7792):605-607
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31992880
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32291526
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1534-3170
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         22
        </volume>
        <issue>
         5
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Current cardiology reports
       </title>
       <isoabbreviation>
        Curr Cardiol Rep
       </isoabbreviation>
      </journal>
      <articletitle>
       Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
      </articletitle>
      <pagination>
       <medlinepgn>
        31
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s11886-020-01291-4
      </elocationid>
      <abstract>
       <abstracttext label="PURPOSE OF REVIEW">
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.
       </abstracttext>
       <abstracttext label="RECENT FINDINGS">
        Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rico-Mesa
        </lastname>
        <forename>
         Juan Simon
        </forename>
        <initials>
         JS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         White
        </lastname>
        <forename>
         Averi
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Anderson
        </lastname>
        <forename>
         Allen S
        </forename>
        <initials>
         AS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Curr Cardiol Rep
      </medlineta>
      <nlmuniqueid>
       100888969
      </nlmuniqueid>
      <issnlinking>
       1523-3782
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2 receptor
      </keyword>
      <keyword majortopicyn="Y">
       ACEI
      </keyword>
      <keyword majortopicyn="Y">
       ARB
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       SARS-COV 2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291526
      </articleid>
      <articleid idtype="doi">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pii">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pmc">
       PMC7154066
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Ther. 2010 Oct;128(1):119-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20599443
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Compr Physiol. 2014 Jul;4(3):1201-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24944035
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Res. 2017 Nov;125(Pt A):21-38
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28619367
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Allergy. 2020 Feb 19;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32077115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):491-494
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056249
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32120458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Saudi Med. 2016 Jan-Feb;36(1):78-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26922692
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trop Med Int Health. 2020 Mar;25(3):278-280
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32052514
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2005 May 24;111(20):2605-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15897343
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2020 Feb 28;368:m810
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32111649
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Feb 24;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105632
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Conn Med. 1965 Oct;29(10):710-1
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         4284109
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32164092
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32291399
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1530-0285
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
       </title>
       <isoabbreviation>
        Mod. Pathol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/s41379-020-0536-x
      </elocationid>
      <abstract>
       <abstracttext>
        Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse alveolar damage. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration, consistent with superimposed bacterial bronchopneumonia. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis is also seen. The heart shows only focal mild fibrosis and mild myocardial hypertrophy, changes likely related to the underlying conditions. In conclusion, the postmortem examinations show advanced diffuse alveolar damage, as well as superimposed bacterial pneumonia in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tian
        </lastname>
        <forename>
         Sufang
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiong
        </lastname>
        <forename>
         Yong
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Huan
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Niu
        </lastname>
        <forename>
         Li
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Jianchun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Meiyan
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China. liaomy@whu.edu.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Shu-Yuan
        </forename>
        <initials>
         SY
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-0484-932X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. syxiao@uchicago.edu.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Pathology, University of Chicago Medicine, Chicago, IL, 60637, USA. syxiao@uchicago.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Mod Pathol
      </medlineta>
      <nlmuniqueid>
       8806605
      </nlmuniqueid>
      <issnlinking>
       0893-3952
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291399
      </articleid>
      <articleid idtype="doi">
       10.1038/s41379-020-0536-x
      </articleid>
      <articleid idtype="pii">
       10.1038/s41379-020-0536-x
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32291137
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1095-9157
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of autoimmunity
       </title>
       <isoabbreviation>
        J. Autoimmun.
       </isoabbreviation>
      </journal>
      <articletitle>
       Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
      </articletitle>
      <pagination>
       <medlinepgn>
        102452
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0896-8411(20)30067-6
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.jaut.2020.102452
      </elocationid>
      <abstract>
       <abstracttext>
        The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Bingwen
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Min
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Zhiguang
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guan
        </lastname>
        <forename>
         Xuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, AdventHealth Orlando, Orlando, USA. Electronic address: xuan.guan.md@adventhealth.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiang
        </lastname>
        <forename>
         Yufei
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China. Electronic address: yufei.xiang@csu.edu.cn.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Autoimmun
      </medlineta>
      <nlmuniqueid>
       8812164
      </nlmuniqueid>
      <issnlinking>
       0896-8411
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus disease 2019
      </keyword>
      <keyword majortopicyn="N">
       Cytokine release syndrome
      </keyword>
      <keyword majortopicyn="N">
       Interleukin-6
      </keyword>
      <keyword majortopicyn="N">
       Tocilizumab
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest No potential conflicts of interest relevant to this review were reported.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291137
      </articleid>
      <articleid idtype="pii">
       S0896-8411(20)30067-6
      </articleid>
      <articleid idtype="doi">
       10.1016/j.jaut.2020.102452
      </articleid>
      <articleid idtype="pmc">
       PMC7151347
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Oral Oncol. 2020 Mar 21;:104659
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32209313
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Reprod Immunol. 2018 Apr;126:60-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29524791
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Respirology. 2006 Nov;11(6):715-22
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17052299
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2014 Jan;88(2):913-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24198408
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29405201
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pediatr Emerg Care. 2009 Sep;25(9):599-602
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19755901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmazie. 2016 Nov 2;71(11):636-639
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29441967
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biol Blood Marrow Transplant. 2016 May;22(5):862-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26551636
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Sep;84(18):9318-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20610717
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2003 Jun 21;326(7403):1358-62
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12816821
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Rheumatol. 2012 Apr;18(3):134-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22426581
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15657466
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Blood. 2014 Jul 10;124(2):188-95
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24876563
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Br J Haematol. 2013 Aug;162(3):376-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23692048
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2005 Feb;75(2):185-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15602737
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Host Microbe. 2016 Feb 10;19(2):181-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26867177
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2011 May;66(5):368-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21310755
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Transplantation. 2010 Oct 27;90(8):825-35
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20697326
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Acta Haematol. 2012;128(2):69-72
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22678422
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Blood. 2013 Aug 22;122(8):1510-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23861248
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-151
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32064853
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2018 Jun;24(6):731-738
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29808005
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2003 May 24;361(9371):1767-72
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12781535
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Pharmacol. 2013 Aug 1;86(3):410-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23707973
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cytokine. 2018 Apr;104:8-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29414327
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2019 May 27;16(1):69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31133031
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Front Immunol. 2019 Jun 21;10:1393
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31293574
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pediatrics. 2007 Sep;120(3):e622-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17698967
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Immunother Cancer. 2018 Jun 15;6(1):56
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29907163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Rheumatology (Oxford). 2011 Feb;50(2):417-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20693540
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2007 Oct;13(10):1248-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17891146
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Infect Immun. 2004 Aug;72(8):4410-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15271897
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2011 Sep 16;146(6):980-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21925319
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ther Apher Dial. 2015 Apr;19(2):178-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25363618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Mol Immunol. 2015 Nov;12(6):681-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25088224
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Invest Dermatol. 2014 Apr;134(4):992-1000
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24213371
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Immunotherapy. 2016 Jul;8(8):959-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27381687
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2017 Nov;72(11):971-980
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28082531
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Respir Res. 2014 Apr 04;15:39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24708472
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drugs. 2019 Jan;79(1):99-103
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30623346
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biol Blood Marrow Transplant. 2017 Sep;23(9):1478-1484
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28495641
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Immunol. 2017 Apr;37(3):273-276
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28265964
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Oncol. 2014 Dec;15(13):1451-1459
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25456364
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2015 Jan;3(1):24-32
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25529339
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Radiology. 2005 Apr;235(1):168-75
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15703312
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Blood. 2005 Oct 1;106(7):2366-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15860669
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Semin Immunopathol. 2017 Jul;39(5):529-539
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28466096
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Shock. 2019 Jul;52(1):83-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30028782
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Autoimmun. 2019 Jun;100:62-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30879886
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Dec 20;367(25):2396-406
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23252526
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2006 Mar 11;367(9513):870-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16530581
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 2011 Nov;92(Pt 11):2542-2548
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21752960
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Allergy Clin Immunol. 2017 May;139(5):1698-1701
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27876626
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Can J Physiol Pharmacol. 2017 Jul;95(7):866-872
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28459157
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Dec 20;367(25):2385-95
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23252525
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Microbiol. 2019 Mar;17(3):181-192
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30531947
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Mil Med Res. 2020 Feb 6;7(1):4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32029004
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2004 Jan 17;363(9404):203-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14738793
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hematol. 2001 Sep;68(1):4-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11559930
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hematol. 2006 Jan;81(1):59-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16369976
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Immunol Methods. 2016 Jul;434:1-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27049586
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28925994
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Rheumatol. 2015 Jun;42(6):994-1001
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25877504
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Mol Immunol. 2016 Jan;13(1):3-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26189369
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Blood. 2017 Dec 21;130(25):2728-2738
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28935695
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2003 May 24;361(9371):1773-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12781536
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2018 Sep;46(9):1411-1420
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29979221
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2013 Apr 18;368(16):1509-1518
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23527958
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Pharmacol Sci. 2004 Jun;25(6):291-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15165741
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2018 Jun;24(6):739-748
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29808007
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Rheum Dis. 2016 Jan;75(1):68-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26056119
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Respir Crit Care Med. 2013 Apr 1;187(7):743-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23348980
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arthritis Rheum. 2012 Dec;64(12):4135-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22886474
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2016;20(4):745-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26957279
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32283980
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1942-7522
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Ear, nose, &amp; throat journal
       </title>
       <isoabbreviation>
        Ear Nose Throat J
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.
      </articletitle>
      <pagination>
       <medlinepgn>
        145561320920762
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1177/0145561320920762
      </elocationid>
      <abstract>
       <abstracttext label="AIM" nlmcategory="UNASSIGNED">
        Pharyngodynia, nasal congestion, rhinorrhea, smell, and taste dysfunctions could be the presenting symptoms of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2. The aim was to perform a systematic review of current evidences on clinical presentation of COVID-19, focusing on upper airway symptoms in order to help otolaryngologists identifying suspected cases.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="UNASSIGNED">
        We searched PubMed and Web of Science electronic databases.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="UNASSIGNED">
        We included 5 retrospective clinical studies for a total of 1556 hospitalized patients with COVID-19, 57.5% were male and mean age was 49.1 years. Pooled data revealed that pharyngodynia was present in 12.4% of patients, nasal congestion in 3.7%, and rhinorrhea was rare. No reports on COVID-19 and olfactory/gustative disorders matched inclusion criteria but preliminary evidences suggested they could be present. Common symptoms were fever (85.6%), cough (68.7%), and fatigue (39.4%). Frequent comorbidities were hypertension (17.4%), diabetes (3.8%), and coronary heart disease (3.8%); 83% of patients had alterations on chest computed tomography that were bilateral in 89.5% of cases. Ground-glass opacity was the most common finding (50%). Lymphopenia (77.2%) and leucopenia (30.1%) were common. Critical cases with complications were 9%, intensive care unit admission was required in 7.3%, invasive ventilation in 3.4%, and mortality was 2.4%.
       </abstracttext>
       <abstracttext label="CONCLUSION" nlmcategory="UNASSIGNED">
        Otolaryngologists should know that pharyngodynia, nasal congestion, olfactory, and gustative disorders could be the presenting symptoms of COVID-19. Clinical presentation together with radiological and laboratory findings could help to identify suspected cases.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Lovato
        </lastname>
        <forename>
         Andrea
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0003-0369-1751
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Neurosciences, University of Padova, Audiology Unit at Treviso Hospital, Treviso, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         de Filippis
        </lastname>
        <forename>
         Cosimo
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Neurosciences, University of Padova, Audiology Unit at Treviso Hospital, Treviso, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Ear Nose Throat J
      </medlineta>
      <nlmuniqueid>
       7701817
      </nlmuniqueid>
      <issnlinking>
       0145-5613
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       nasal congestion
      </keyword>
      <keyword majortopicyn="N">
       pharyngodynia
      </keyword>
      <keyword majortopicyn="N">
       smell
      </keyword>
      <keyword majortopicyn="N">
       taste
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32283980
      </articleid>
      <articleid idtype="doi">
       10.1177/0145561320920762
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32279908
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1873-5487
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          04
         </day>
        </pubdate>
       </journalissue>
       <title>
        Archives of medical research
       </title>
       <isoabbreviation>
        Arch. Med. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0188-4409(20)30378-7
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.arcmed.2020.03.011
      </elocationid>
      <abstract>
       <abstracttext>
        In the recent coronavirus disease (COVID-19) outbreak, a higher proportion of patients with severe disease were found in older persons with comorbidities. This observation has been related to the use of drugs that can increase the cellular expression of angiotensin-converting enzyme 2 (ACE2) that has been recognized as target to which the virus bind to cells. Although this hypothesis is possible, it may also have other explanations which are discussed.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gracia-Ramos
        </lastname>
        <forename>
         Abraham Edgar
        </forename>
        <initials>
         AE
        </initials>
        <affiliationinfo>
         <affiliation>
          Departamento de Medicina Interna, Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico. Electronic address: dr.gracia.dmm@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        04
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Arch Med Res
      </medlineta>
      <nlmuniqueid>
       9312706
      </nlmuniqueid>
      <issnlinking>
       0188-4409
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus infections
      </keyword>
      <keyword majortopicyn="N">
       Diabetes mellitus
      </keyword>
      <keyword majortopicyn="N">
       Hypertension
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32279908
      </articleid>
      <articleid idtype="pii">
       S0188-4409(20)30378-7
      </articleid>
      <articleid idtype="doi">
       10.1016/j.arcmed.2020.03.011
      </articleid>
      <articleid idtype="pmc">
       PMC7128661
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        BMC Public Health. 2018 May 2;18(1):574
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29716568
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2018 May 29;137(22):2344-2356
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29449338
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2014 Feb;27(2):252-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24108862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Coll Cardiol. 2019 Jun 25;73(24):3135-3147
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31221263
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Aging Dis. 2018 Feb 1;9(1):143-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29392089
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Diabetes. 2015 Mar;7(2):166-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24809622
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2013 Sep 4;310(9):948-59
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24002281
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2015 Sep 5;386(9997):995-1007
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26049252
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>